Stock comparison
LeMaitre Vascular
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 72B | LMAT |
| Benjamin Graham | 89A | 75B | LMAT |
| Philip Fisher | 81C | 75B | LMAT |
| Peter Lynch | 67B | 58C | LMAT |
| Joel Greenblatt | 56D | 47D | LMAT |
| Charlie Munger | 68D | 69B | RMD |
| Terry Smith | 69D | 73B | RMD |
Side-by-side metrics
| Metric | LMAT | RMD |
|---|---|---|
| Market cap | $2.23B | $30.18B |
| P/E (TTM) | 37.1x | 19.6x |
| EV/EBIT | 36.6x | 17.1x |
| ROIC (TTM) | 9.43% | 19.63% |
| Gross margin | 72.39% | 61.69% |
| Net margin | 24.35% | 27.44% |
| Revenue CAGR 5y | 12.75% | 12.64% |
| EPS CAGR 5y | 19.04% | 30.73% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Gross margin72.39%vs 61.69%+15%
RMD leads on
- Market cap$30.18Bvs $2.23B+93%
- Debt / Equity0.1xvs 0.5x+72%
- EV/EBIT17.1xvs 36.6x+53%
- ROIC (TTM)19.63%vs 9.43%+52%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.